While other MediaPost newsletters and articles remain free to all ... our new Research Intelligencer service is reserved for paid subscribers ...
Subscribe today to gain access to every Research Intelligencer article we publish as well as the exclusive daily newsletter, full access to The MediaPost Cases, first-look research and daily insights from Joe Mandese, Editor in Chief.
The Public Citizen report said off-label promotion of drugs was the No. 1 reason for pharmaceutical-company penalties in recent years. In the past five years, off-label penalties have increased
six-fold over the previous 15 years.
Leading the charge: Pfizer Inc. and GlaxoSmithKline.
